不同功能化基团修饰的硅壳纳米颗粒分散性研究

采用反相微乳液体系中功能化基团同步修饰(油相修饰)以及反相微乳液制备纳米颗粒后再通过功能化基团后续修饰(水相修饰)的方法分别制备了纯硅壳纳米颗粒(SiNP)、氨基化硅壳纳米颗粒(NSiNP)、羧基化硅壳纳米颗粒(CSiNP)和聚乙二醇硅壳纳米颗粒(PSiNP). 通过沉降时间和离心速度观察了不同方法获得的不同功能化基团修饰的硅壳纳米颗粒在水中的分散及稳定性, 并采用激光粒度仪、透射电子显微镜对分散效果进行了分析. 结果表明, 采用同一修饰方法分别制备的纳米颗粒在水中的分散及稳定性顺序是CSiNP≥PSiNP>SiNP>NSiNP; 油相修饰法获得的CSiNP和PSiNP的分散性要优于水相修饰法获得的. PSiNP和CSiNP在Hela细胞表面的非特异性吸附非常小, 而NSiNP却显示了强烈的细胞非特异性吸附.     

γ-聚谷氨酸/壳聚糖纳米颗粒的制备及pH响应释放性能

利用生物相容性良好的γ-聚谷氨酸(γ-PGA)和壳聚糖(CS)制备表面分别带正、负电荷的pH响应性纳米颗粒,并用其包载抗生素阿莫西林。利用动态光散射仪、傅里叶红外光谱仪、X射线衍射和透射电镜对载药纳米颗粒的结构和形貌进行表征,考察两种纳米载体的pH响应释放药物能力及其对细胞的毒性。研究结果表明,带负电荷的纳米颗粒显示出更好的pH响应控释药物的能力。在模拟胃部环境下,载药纳米颗粒的粒径大小稳定在200～300 nm,药物释放量仅为25%。在中性至弱碱性的肠道细胞间隙下,其粒径增大到1μm左右,药物释放量增加到85%。此外,细胞毒性实验表明该药物载体对细胞没有毒性,载药纳米颗粒对肠道细菌的抑制效果比游离药物的更好。     

Fe3O4@mMoO3介孔多功能纳米载体的制备及其微波响应药物传递

以氨基功能化的Fe_3O_4纳米颗粒为磁核,结合直接沉淀法和模板法在其表面包覆上介孔MoO_3层,制备磁性-微波热转换性-介孔结构于一体的多功能核-壳结构复合纳米载体Fe_3O_4@mMoO_3,并对其结构、载药及微波控制靶向给药性进行研究。TEM图表明所得的复合纳米载体具有明显的核壳结构,完美的球形,且壳层中有清晰的孔状结构。磁性和微波热转换特性分析表明,该复合载体兼具良好的磁性和微波热转换特性,可实现药物的靶向可控给药。以布洛芬(IBU)为模型药物,对该复合纳米载体的药物负载能力和微波响应可控释放性进行研究,结果表明,在持续微波辐射90 s时IBU的释放率达到90%,远远高于仅搅拌时的释放率。     

三层同轴电喷-去模板法制备核壳纳米颗粒用于蛋白质药物输送

分别以聚乙二醇(PEG)、聚(丙交酯-乙交酯)(PLGA)和牛血清白蛋白(BSA)为冠、壳和核层材料,采用三层同轴电喷技术制备得到微米颗粒.激光共聚焦显微镜(LSCM)显示,该方法制备得到的微米颗粒呈现核-壳-冠结构.通过脱去该微米颗粒的PEG冠层(模板),得到包载有BSA的纳米颗粒.研究发现,随着壳层PLGA溶液进样速度的减慢,去模板后纳米颗粒的粒径从约146 nm减小到68 nm.BSA在纳米颗粒中的包埋率可高达78.3%,并且其释放没有显著的药物暴释现象.圆二色谱结果表明,同轴电喷过程对BSA二级结构影响很小.因此,利用三层同轴电喷-去模板法可制备得到粒径可调控的蛋白质纳米载体系统,并且该过程中蛋白质的结构基本维持不变.     

光催化还原制备Au/Ag核壳结构纳米粒子及其修饰电极的电催化性能

以Keggin结构硅钨杂多酸H4SiW12O40(SiW12)为光催化还原剂,通过光化学还原法制备Au/Ag核壳结构纳米粒子. 透射电子显微镜分析显示,所得纳米粒子粒径为30～40 nm,呈均匀分散的球形颗粒,该制备方法的特点是可以较好的避免单金属纳米粒子的形成. 将Au/Ag核壳纳米粒子修饰到具有PVP膜的玻碳电极表面,得到SiW12-(Au/Ag)-PVP多层膜修饰电极. 该修饰电极在0.5 mol/L H2SO4介质中具有良好的电化学响应,在0～-0.75 V电位范围内,出现了3对归属于SiW12的氧化还原峰,且电极性能稳定,灵敏度高. 对H2O2的电催化还原性能明显优于单金属Ag纳米粒子修饰电极,说明Au核的存在可以很好的改善Ag的电催化性能,Au和Ag之间存在相互协同催化作用.     

聚合物胶束作为药物载体的研究进展

聚合物胶束是具有疏水核心和亲水壳的自组装纳米颗粒.作为一种新型的药物载体,聚合物胶束具有载药范围广、结构稳定、体内滞留时间长、毒副作用小等特点.可以通过肿瘤组织的高通透性和滞留效应被动地富集在癌组织中,也可以通过修饰聚合物胶束的表面基团来实现药物靶向给药.本文总结并分析了聚合物胶束作为药物载体的研究进展,包括聚合物胶束的功能特点、制备、应用和药物的包载.     

同轴电喷-去模板法制备具有金属基质蛋白酶响应性的纳米载体

通过化学键偶联的形式在聚乳酸(PLA)分子链中引入了可被金属基质蛋白酶(MMP-2)特异性降解的多肽peptide(GPLGIAGQ)单元,得到具有金属基质蛋白酶响应性的聚合物PLA-b-peptide-b-PLA.通过同轴电喷方法制备得到以PLA-b-peptide-b-PLA和抗肿瘤药物DOX的混合物作为内核,亲水性聚乙二醇(PEG)作为外壳的,具有核-壳结构的载药微球.其中水溶性的PEG壳层可在水环境中迅速脱除,将载药微球的尺寸从微米级减小到纳米尺度,可以达到药物载体系统在输运的循环过程中的尺寸递减.制备的纳米载体可在金属基质蛋白酶存在的环境中,响应性释放所包载的抗肿瘤药物,实现药物的控制释放.     

水滑石型磁性纳米载药粒子的制备及其体外药物释放性能研究

通过调变镁铁尖晶石的含量, 采用一步共沉淀法制备了一系列具有核壳结构的水滑石型磁性纳米载药粒子, 对其微结构、热稳定性、磁性和药物释放性能进行了系统的研究. 结果表明这种磁性纳米载药粒子是一种具有以镁铁尖晶石为核层、双氯酚酸(Diclofenac, DIC)插层水滑石(DIC-LDH)为壳层的复合纳米粒子, 粒径在90～180 nm之间. 其中壳层DIC-LDH的晶粒尺寸D₁₁₀和层板电荷密度随磁核含量的增大而逐渐减小. 磁性纳米载药粒子的载药量随磁核含量的增大而逐渐减小, 而其比饱和磁化强度则随着磁核含量的增大逐渐增大. 体外释放实验表明, 无外加磁场时, 磁核含量增大, 壳层DIC-LDH粒径减小, 磁性纳米载药粒子药物释放速率逐渐增大|外加1500 G磁场时, 磁核含量增大, 磁致团聚程度增大, 其药物释放速率逐渐减小.     

载紫杉醇星型M-PLA-TPGS纳米颗粒的合成及其用于前列腺癌治疗药物载体的研究

合成了一种甘露醇引发的星型共聚物甘露醇-聚乳酸-聚乙三醇1000维生素E琥珀酸酯(M-PLATPGS).利用纳米沉淀法制备载紫杉醇M-PLA-TPGS纳米颗粒.纳米颗粒近似球形,粒径分布较窄.对载药纳米颗粒进行粒径、表面电荷、载药量、包封率和体外药物释放的表征,结果表明,体外药物释放呈双相释放模型,M-PLA-TPGS纳米颗粒在前列腺癌PC-3细胞中的摄取水平要高于PLGA和PLA-TPGS纳米颗粒.载紫杉醇M-PLA-TPGS纳米颗粒对于前列腺癌细胞的的毒性显著高于载紫杉醇PLA-TPGS纳米颗粒和商业制剂Taxol,证明星型M-PLA-TPGS聚合物作为纳米药物载体优于线性PLGA和PLA-TPGS聚合物.     

介孔硅纳米储存器在智能药物释放系统的应用

开发新型细胞微环境刺激响应性智能药物控释系统是目前材料学、药理学与临床医学研究的共同热点之一,其目的在于寻求合适的药物载体,提高药物的安全性、有效性及降低药物毒副作用。本文综述了介孔硅功能复合纳米材料在生物医药领域的应用研究进展;通过对其进行特定的化学修饰、生物修饰、物理修饰,不仅能特异性细胞识别靶向,还能针对病变细胞实现药物定点、定时、定量的“生物爆破”释放;这在药物可控释放、靶向癌症治疗、靶向基因递送等领域展示了其广阔的应用前景。同时,本文还系统地分析和总结了各种智能响应性介孔硅纳米储存器的制备方法和响应机制,包括“无机纳米塞-介孔硅”纳米智能控释系统、“有机大分子控制器-介孔硅”智能功能复合型控释系统、“分子开关控制器-介孔硅”自响应性纳米控释系统等,这为设计新型响应性介孔硅纳米储存器系统提供了借鉴与思路。     

载药荧光纳米粒子的制备及在乳腺癌MCF-7细胞系的应用及效果评价

利用两亲性聚乙二醇-聚乳酸共聚物（PEG-PDLLA）包覆荧光染料（DPBA）和紫杉醇（PTX）,通过自组装方法制得载药荧光纳米粒子DPBA/PTX@PEG-PDLLA.纳米粒子尺寸均一,具有良好的生物相容性.对纳米粒子的发光性质、载药量和体外药物释放等进行了表征,并考察了纳米粒子对乳腺癌细胞MCF-7的抑制效果,观察了MCF-7细胞对纳米粒子的摄取情况.结果表明,DPBA/PTX@PEG-PDLLA纳米粒子具有较强的红光发射,不仅可以用于MCF-7肿瘤细胞质荧光成像,而且对肿瘤细胞的增殖具有一定的抑制能力.     

Novel drug delivery system of hollow mesoporous silica nanocapsules with thin shells: preparation and fluorescein isothiocyanate (FITC) release kinetics

Core-shell nanoparticles of Au@silica with a diameter of approximate 45–60 nm and wall thickness in range of 3–10 nm were synthesized by using 40 and 50 nm gold nanoparticles as the templates. The mesoporous particles are regulated by 3-aminopropyltrimethoxysilane addition. Hollow mesoporous silica nanocapsules (HMSNs) were prepared by using sodium cyanide to dissolve the gold cores. The characterization of Au@silica and HMSNs by transmission electronic microscope indicated that the silica shells were uniform and smooth, and also the porosity was proved by fluorescein isothiocyanate (FITC) release experiments. The ratio of hollow core to HMSNs is more than 70%. HMSNs were subsequently used as drug carrier to investigate FITC (as a model drug) release behaviors in vitro. Fluorescent spectrometry was performed to determine the release kinetics from the HMSNs. The release profiles are significantly different as compared with the control (free FITC), which show that HMSNs are good drug carriers to control drug release, and have high potential in therapeutic drugs delivery in future applications.     

Hydrophobic Particle Effects on Hydrate Crystal Growth at the Water–Oil Interface

This study introduced hydrophobic silica nanoparticles (SiNPs) into an interface of aqueous and hydrate‐forming oil phases and analyzed the inhibition of hydrate crystal growth after seeding the hydrate slurry. The hydrate inhibition performance was quantitatively identified by micro‐differential scanning calorimetry (micro‐DSC) experiments. Through the addition of 1.0 wt % of SiNPs into the water–oil interface, the hydrate crystal growth only occurred around the seeding position of cyclopentane (CP) hydrate slurry, and the growth of hydrate crystals was retarded. Upon a further increase in the SiNP concentration up to 2.0 wt %, the SiNP‐laden interface completely prevented hydrate growth. We observed a hollow conical shape of hydrate crystals with 0.0 and 1.0 wt % of SiNPs, respectively, but the size and shape of the conical crystals was shrunken at 1.0 wt % of silica nanoparticles. However, the conical shape did not appear with an increased nanoparticle concentration of 2 wt %. These findings can provide insight into hydrate inhibition in oil and gas delivery lines, possibly with nanoparticles.     

壳聚糖/乙酰半胱氨酸纳米粒子的性质及体外释药性

制备了一种基于壳聚糖/乙酰半胱氨酸偶合物(CS-NAC)的新型巯基纳米粒子并进行了结构表征, 同时对纳米粒子的黏附性、溶胀性和药物释放进行了测试. 结果表明, 纳米粒子具有较小的粒径(140~210 nm)和正的表面电位(19.5~31.7 mV), 胰岛素的载药量达到13%~42%. 这些性质随着巯基含量的变化而变化. 与壳聚糖纳米粒子相比, 巯基壳聚糖纳米粒子表现出了更强更快的黏附性质. 体外释放研究结果表明, 巯基壳聚糖纳米粒子的胰岛素释放具有pH响应性. 在pH=6.8时, 15 min即能释放58.6 %的胰岛素; 而在pH=5.4时, 24 h内仅有不到40%的胰岛素被释放. 因此, CS-NAC纳米粒子用于胰岛素的黏膜给药体系具有很好的应用前景.     

pH响应的介孔二氧化硅纳米颗粒的制备及可控释放

选择带负电荷且溶解度和分子结构对pH值非常敏感的聚丙烯酸作为封堵分子, 采用静电吸附的修饰方法, 制备了pH响应的MCM-41型介孔二氧化硅纳米颗粒. 利用高倍透射电子显微镜(TEM)、 X射线衍射(XRD)、 傅里叶变换红外光谱(FTIR)及比表面积分析等手段表征了介孔二氧化硅纳米颗粒的物理化学性质. 以联钌吡啶染料分子作为模式客体分子, 研究了pH调控下的模式客体分子在介孔二氧化硅纳米颗粒中的包裹及释放行为. 结果表明, 该介孔二氧化硅纳米颗粒对pH具有很好的响应性; 在近中性条件下, 带正电的二氧化硅纳米颗粒通过静电吸附作用吸附带负电的聚丙烯酸, 导致介孔封堵, 使包载的染料分子几乎无释放; 客体分子的释放率随着pH值的降低而升高, 当pH≤5时, 染料分子显著释放, pH=1时客体分子的释放率高达98％, 可以实现对包载客体分子的控制释放. 该pH响应的介孔二氧化硅纳米颗粒载体具有制备简便、 价格低廉和包载量大等优点, 有望应用于药物的控制释放.     

A new method for pH triggered curcumin release by applying poly(l-lysine) mediated nanoparticle-congregation

We introduce a novel method for encapsulation of curcumin by synthesizing microcapsule containing self-assembled nanoparticles using poly (l-lysine), trisodium citrate and silica sol. Such microcapsules can only be prepared in neutral and alkaline environment and unencapsulated curcumin can be effectively removed by simple centrifugation with encapsulation efficiency 57.34%. The particle sizes are in the range 0.7–3 μm with an effective diameter 1.05 μm. The structure of the microcapsules is dependent upon the solubility of curcumin in the solvent environment, the microcapsule are spherical when prepared in 10% acetone and bowl-shaped/conical when prepared in water suspension, however, the size of these curcumin encapsulated microcapsules remain similar. Fluorescence microscope images confirm that curcumin is predominantly concentrated within the shell wall of the capsules. Photophysical behavior of Micro-curcumin with respect to curcumin alone is evaluated. Release of curcumin is found to be triggered by pH where acidic environment trigger maximum release compared to basic and neutral conditions. Micro-curcumin is as stable as curcumin. Drug release efficiency is found to be 61.44% and the drug release profile of Micro-curcumin follow Higuchi model. It is also revealed that β-diketone group of curcumin responsible for scavenging activity is retained in the Micro-curcumin, thus suggesting applicability of such system as a poorly water soluble drug delivery vehicle. In contrast to other curcumin delivery systems, the presented method is easy, fast and does not need flow rate monitoring device. In addition poly (l-lysine) as a non-toxic and highly stable material that prevents metabolic degradation is used in the present preparation method.     

Preparation and Characterization of Thermosensitive Nanoparticles for Targeted Drug Delivery

In this study, we have reported novel thermosensitive nanoparticles formulated by an emulsion-solvent evaporation technique using acetaminophen (AAP) as a model drug. The high entrapment efficiency of nanoparticles was 68.56%, particle size about 240.6 nm and zeta potential ?27 mV. Furthermore, the drug release was also investigated both at 37°C and 42°C, respectively. The goal of our study was to obtain a targeted drug delivery system, exploiting the temperature-sensitive behavior. In contrary to normal temperature (37°C), the release rate of AAP was found to noticeably increase at high temperature (42°C) with a larger cumulative amount of drug released. In this way, it would lead to production of nanoparticles having a high thermosensitive behavior on drug release. Thus, this new strategy has the potential to control drug release at the diseased site for targeted drug delivery system (TDDS) with positive temperature-controlled.     

Chitosan nanoparticles crosslinked by glycidoxypropyltrimethoxysilane for pH triggered release of protein

pH-responsive-chitosan nanoparticles for the control release of protein drug were prepared by combining two-step crosslinking method,in which chitosan was subsequently crosslinked by sodium tripolyphosphate(TPP)and glycidoxypropyltrimethoxysilane (GPTMS).Compared with TPP crosslinked chitosan particles,the two-step crosslinked nanoparticles were not only pH-responsive but also more stable in wide pH range.Fluorescein isothiocyanate(FITC)labeled anti-human-IgG antibody was used as a model protein drug for...     

Stimuli‐responsive zein‐based nanoparticles as a potential carrier for ellipticine: Synthesis,release, and in vitro delivery

In the present research, we have investigated a drug delivery system based on the pH‐responsive behaviors of zein colloidal nanoparticles coated with sodium caseinate (SC) and poly ethylene imine (PEI). These systematically designed nanoparticles were used as nanocarriers for encapsulation of ellipticine (EPT), as an anticancer drug. SC and PEI coatings were applied through electrostatic adsorption, leading to the increased size and improved polydispersity index of nanoparticles as well as sustained release of drug. Physicochemical characteristics such as hydrodynamic diameter, size distribution, zeta potential and morphology of nanoparticles prepared using different formulations and conditions were also determined. Based on the results, EPT was encapsulated into the prepared nanoparticles with a high drug loading capacity (5.06%) and encapsulation efficiency (94.8%) under optimal conditions. in vitro experiments demonstrated that the release of EPT from zein‐based nanoparticles was pH sensitive. When the pH level decreased from 7.4 to 5.5, the rate of drug release was considerably enhanced. The mechanism of pH‐responsive complexation in the drug encapsulation and release processes was extensively investigated. The pH‐dependent electrostatic interactions and drug state were hypothesized to affect the release profiles. Compared to the EPT‐loaded zein/PEI nanoparticles, the EPT‐loaded zein/SC nanoparticles exhibited a better drug sustained‐release profile, with a smaller initial burst release and longer release period. According to the results of in vitro cytotoxicity experiments, drug‐free nanoparticles were associated with a negligible cytotoxicity, whereas the EPT‐loaded nanoparticles displayed a high toxicity for the cancer cell line, A549. Our findings indicate that these pH‐sensitive protein‐based nanoparticles can be used as novel nanotherapeutic tools and potential antineoplastic drug carriers for cancer chemotherapy with controlled release.